Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Previous Page Next Page

The following table summarises how oncogenic activation of TRK proteins can arise.

Table 1: Mechanisms of TRK Protein Activation

Mutations

The effect of the majority of NTRK gene mutations on tumourigenesis and progression has not been determined [1]. However, some point mutations (NTRK1 p. G667C, NTRK3 p. G696A) may arise from acquired resistance  to TRK inhibitors [2].

Splice variants

NTRK gene splice variants have been detected in neuroblastoma and acute myeloid leukaemia [1].

Gene fusions

These are the most common mechanisms of oncogenic activation of NTRK genes [1] and currently the most promising aberration for use as a therapeutic target.

References

  1. Cocco E, Scaltriti M, Drilon A. NTRK fusion-positive cancers and TRK inhibitor therapy. Nat Rev Clin Oncol 2018; 15: 731-747.
  2. Okamura R, Boichard A, Kato S et al. Analysis of NTRK Alterations in Pan-Cancer Adult and Pediatric Malignancies: Implications for NTRK-Targeted Therapeutics. JCO Precis Oncol 2018; 2018.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings